Vector Development

Enhancer Interference Reduced By Creating Novel Adenoviral Transgene Cloning Site

Published in Gene Therapy Weekly, April 12th, 2001

by Deborah W. Heinrich, staff medical writer - A novel adenoviral transgene cloning site in the right inverted terminal repeat (ITR) of Ad5 reduces background EA1 enhancer expression and restores tissue specific promoter regulation, report Medical University of South Carolina researchers.

Use of recombinant adenoviral vectors for delivery of tissue-specific transgenes is an important protocol in gene therapy. Therapeutic genes are commonly inserted within the E1A gene of the adenoviral genome. Researchers have found, however, that genes expessed from within this site tend to lose tissue-specific promoter regulation.

S. Rubinchik and colleagues...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry